Concord Biotech shares gain 5% after bagging USFDA approval for $500 million drug

Shares of Concord Biotech Ltd. gained as much as 5% on Wednesday, June 10, after the company announced that it has secured approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in both 5 mg and 10 mg strengths.

The clearance marks a step forward in enabling the company expand its product portfolio in the US market.

What Are Tofacitinib Tablets Used For?

Tofacitinib tablets serve as an essential treatment option for patients suffering from several chronic and autoimmune conditions. The approved medication is indicated for the treatment of adult patients managing the following health challenges:

• Moderately to severely active rheumatoid arthritis (RA)


• Active psoriatic arthritis (PsA)


• Active ankylosing spondylitis (AS)


• Moderately to severely active ulcerative colitis (UC)


• Active polyarticular course juvenile idiopathic arthritis (pcJIA)

How Big Is The US Market For Tofacitinib?

The US market for Tofacitinib Tablets is substantial, with combined market estimates for both dosage strengths valued at approximately $500 million. By obtaining this USFDA approval, Concord Biotech is well-positioned to leverage these attractive market opportunities.

According to the company, this development aligns directly with its long-term growth strategy, aimed at reinforcing its commercial footprint across both US and international markets. The company’s ability to secure this approval underscores its commitment to enhancing its product offerings and delivering specialized pharmaceutical solutions to a global patient base.

Shares of Concord Biotech are trading 4.9% higher on Wednesday after the announcement at ₹1,334.7. The stock has gained in six out of the last eight trading sessions, during which the stock has gained 25%.